Mini-Reviews in Medicinal Chemistry
September 18, 2026
Fatemeh Abolhasani, Hojjat Rezaiezadeh, Mohammad Amin Langarizadeh et al.
Psilocybin, a compound found in certain species of Psilocybe mushrooms, shows potential as a treatment for various psychiatric conditions. In the past decade, a growing body of evidence has shown the effectiveness of psilocybin in treating conditions, such as treatment-resistant depression, generalized anxiety disorder, post-traumatic stress disorder, and substance use disorders. This review...
ACS Chemical Neuroscience
September 15, 2026
Lindsay P. Cameron, Matthew W. Johnson, Kevin S. Murnane et al.
Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the...
Behavioral Sleep Medicine
September 12, 2026
Gina Fisher, Amber B. Cohen, Emina Prguda et al.
Objectives The study examined the psychometric properties of the Nightmare Distress Questionnaire (NDQ) in veterans with a provisional posttraumatic stress disorder (PTSD) diagnosis and trauma-related nightmares.Method Participants were 659 Australian Defence Force veterans who completed online questionnaires for a larger study investigating military-civilian transition. Analyses included...
Clinical Journal of Pain
September 10, 2026
Colin Calvert, Emily M Hagel Campbell, Lee J. S. Cross et al.
OBJECTIVES: Little is known about who benefits most from Mindfulness-Based Interventions (MBIs), and whether certain groups differentially benefit from different types of MBI formats (group-based versus non-group based). The present study uses data from a three-arm randomized controlled trial (ClinicalTials.gov ID: NCT04526158) of two MBIs (self-paced and group) to test moderating effects by...
Frontiers in Sleep
September 9, 2026
Brian D. Robertson, Emily F. Wargo, Joel Fay
Objective Nightmares are a common, distressing condition among individuals with post-traumatic stress disorder (PTSD) and are associated with impaired sleep quality and elevated suicide risk. First responders carry a substantial burden of occupational trauma and PTSD yet are under-represented in nightmare-treatment research. NightWare is an FDA-authorized prescription wearable that monitors...
The International Journal of Neuropsychopharmacology
September 9, 2026
R Freire, C Chaves, M Cabo et al.
Abstract Background Anxiety disorders are among the most prevalent psychiatric disorders worldwide, causing significant impacts on physical and emotional health and substantial functional impairment. Not only individuals with anxiety disorders have severe and debilitating anxiety symptoms; patients with PTSD, OCD and mood disorders often present with anxiety. The term classic psychedelics...
The International Journal of Neuropsychopharmacology
September 9, 2026
J Vieira-Andrade, I Marques, M Brito
Abstract Background Serotonin 2A receptor (5-HT2AR) agonists play a crucial role in multiple cognitive processes, namely executive functions, learning and memory. Owing partly to this, psychedelics such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), mescaline and ayahuasca might be valuable adjuvants in improving memory deficits and language impairment. Thanks to...
The Family Journal
September 7, 2026
Whitney Biancur, Stephen Southern
Written accounts of the 1666 Great Fire of London by diarist Samuel Pepys, as well as recent survivors of wildfires in Southern California, document the stressful aftermath of the natural disasters and the development of post-traumatic stress symptoms (PTSS) in the following months. Their accounts highlight the prominence of sleep disturbance in the etiology of post-traumatic stress disorder...
The Journal of Clinical Pharmacology
September 1, 2026
Neil McNaughton, Ben Beaglehole, Paul Glue
The dose-response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment-resistant depression, post-traumatic stress disorder, generalized and/or social anxiety, or obsessive-compulsive disorder. For each disorder, they received single intramuscular doses of racemic ketamine (0.5 and 1.0...
The International Journal of Neuropsychopharmacology
September 1, 2026
N Hartman, D Ivkic, M C Dorczok et al.
Neuropsychiatric manifestations of Long COVID (LC) frequently include post-exertional malaise (Cheng et al. , 2025), fatigue, cognitive dysfunction and impairment, sleep disturbances, post-traumatic stress, autonomic dysregulation, pain, inner tension, psychomotor retardation, aberrations in appetite and weight (Badenoch et al. , 2022; O'Mahoney et al. , 2025), showing substantial clinical and...